Brought to you by 
Actelion spins out new firm as part of its acquisition by J&J; later named Idorsia, includes assets of Actelion's Vaxxilon division
18 Aug 2020
Executive Summary
As part of its $30bn cash acquisition by Johnson & Johnson, Actelion Ltd. is spinning out its drug discovery operations and early-stage clinical assets into a new Swiss biopharma company (R&D NewCo).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Divestiture/Spin-Out
- Full Acquisition
- Includes Earnout
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Actelion spins out new firm as part of its acquisition by J&J; later named Idorsia, includes assets of Actelion's Vaxxilon division
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice